KLOW Peptide: Blend Ingredients, Research & Dosage Chart

KLOW peptide is a 4-in-1 research blend of GHK-Cu, BPC-157, TB-500, and KPV. See what is inside, why it is blue, KLOW vs GLOW, and a dosage reference chart.

KLOW peptide is a four-in-one research blend that combines four separately studied peptides into a single vial: GHK-Cu, BPC-157, TB-500, and KPV. In its most common format, the 80 mg "KLOW blend" vial, the four are present at a fixed ratio of 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. The name is a direct extension of the older GLOW blend: GLOW contains the first three peptides, and adding KPV (the "K") produces KLOW.

The compound has gained rapid interest in 2026. Most of that interest is informational: people want to know what is in it, what each component has been studied for, how the blend is reconstituted, and how it differs from GLOW. This guide answers those questions using primary preclinical literature rather than marketing claims. KLOW and its components are sold strictly as research-use-only (RUO) materials and are not approved for human use.

What Is the KLOW Peptide Blend?

KLOW is a combination of four research peptides formulated together so that each contributes a distinct, well-characterized mechanism. Three of the four (GHK-Cu, BPC-157, and TB-500) are studied mainly in tissue and wound models, while the fourth (KPV) is studied mainly in inflammation models. Combining peptides with overlapping but non-identical pathways is what researchers refer to when they describe the blend as "synergistic," though it is worth noting that the synergy of the specific four-peptide combination has not itself been validated in controlled human trials.

The standard commercial format is labeled "KLOW", or "KLOW 80", where 80 refers to the total lyophilized (freeze-dried) peptide mass across all four components in a single vial. The component breakdown below reflects the ratio most widely listed by research suppliers.

Note: not every vial labeled "KLOW" uses the 50/10/10/10 ratio. Some suppliers list different totals or split the four peptides evenly, so the certificate of analysis for a specific vial is the only reliable source for its exact composition.

What Is in KLOW Peptide? The Four Components Explained

Each peptide in KLOW has its own chemistry, its own body of research, and its own mechanism. Understanding the blend means understanding the four parts.

GHK-Cu (the copper tripeptide)

GHK-Cu is glycyl-L-histidyl-L-lysine bound to a copper(II) ion, a tripeptide first isolated from human plasma in 1973 by Loren Pickart. In cultured fibroblasts, it has been studied for its effect on extracellular matrix signaling: one classic in vitro series reported that GHK-Cu stimulated collagen synthesis in fibroblast cultures beginning at concentrations around 10⁻¹² M and reaching maximal stimulation near 10⁻⁹ M. Later bioinformatic analyses by Pickart and colleagues reported that GHK can shift the expression of more than 4,000 human genes, many tied to matrix remodeling. These are laboratory observations in cell and gene-expression models, not demonstrated outcomes in humans. GHK-Cu also appears in other recovery-focused blends covered in our injury-recovery peptide research guide.

BPC-157 (the pentadecapeptide)

BPC-157 is a stable pentadecapeptide, a 15-amino-acid sequence derived from a protein found in gastric juice. In rodent tendon and muscle models it has been studied for its effect on cell migration and angiogenesis (new blood-vessel formation). In one in vitro study, BPC-157 increased the outgrowth and migration of tendon fibroblasts in a dose-dependent manner and up-regulated the growth-hormone receptor in those cells. In rodent healing models, researchers reported that BPC-157 modulated angiogenesis through the VEGFR2-Akt-eNOS signaling pathway. Evidence for BPC-157 remains preclinical, and no large controlled human trials have confirmed these findings.

TB-500 (a thymosin beta-4 fragment)

TB-500 is a synthetic peptide based on a segment of thymosin beta-4 (Tβ4), a 43-amino-acid protein present in most cells. Its best-characterized mechanism is actin regulation: through the LKKTET binding motif it sequesters G-actin and influences how cells build and dismantle their internal scaffolding, which is central to cell migration. In scratch-assay and keratinocyte models, Tβ4 has been reported to accelerate cell migration roughly two- to three-fold over controls at very low concentrations. As with the other components, these are findings in cultured cells and animal models rather than approved human results.

KPV (the anti-inflammatory tripeptide)

KPV is a tripeptide made of lysine, proline, and valine, corresponding to residues 11 to 13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the component that distinguishes KLOW from GLOW. In inflammation models, KPV has been studied for its ability to enter cells through the PepT1 transporter and reduce NF-κB nuclear translocation, with some models reporting reductions of up to roughly 80 percent and corresponding drops in pro-inflammatory cytokines such as TNF-alpha and IL-6. In murine colitis models, orally delivered KPV reduced measured colitis severity. This research is concentrated in gut-inflammation models and has not been extended to approved human use.

KLOW Peptide Benefits: What the Component Research Actually Shows

Because KLOW itself has not been tested as a fixed four-peptide blend in controlled human trials, any discussion of "benefits" is really a summary of what each separate component has been studied for in preclinical settings. Grouped by research theme, the documented effects of the individual peptides include:

Each of these is an observation from a specific model system. None has been established as a clinical outcome for the KLOW blend in humans, and reported social-media "before and after" results are anecdotal rather than controlled data.

KLOW vs GLOW Peptide: What Is the Difference?

The difference between KLOW and GLOW is one peptide. GLOW is a three-peptide blend of GHK-Cu, BPC-157, and TB-500. KLOW is the same three plus KPV. In practical research terms, KLOW adds a dedicated anti-inflammatory tripeptide to a blend that is otherwise focused on tissue and matrix models.

KLOW Peptide Dosage Chart and Reconstitution (Research Reference)

The figures researchers reference for KLOW follow directly from the 80 mg ratio. Reconstitution is the process of adding sterile or bacteriostatic water to the freeze-dried powder to create a measurable liquid. The chart below shows how the four components distribute when a standard KLOW 80 vial is reconstituted, and is provided only as a laboratory reference for handling research materials, not as guidance for human use.

On a standard U-100 insulin syringe, 0.1 mL equals 10 units, which is why supplier charts often describe amounts in "units." The exact figures change with the volume of water used: adding 1 mL instead of 2 mL doubles the concentration. Because KLOW is a research-use-only material, these calculations are intended for laboratory measurement accuracy and not as a dosing recommendation for people.

KLOW Blend Reconstitution Guide

Learn how to reconstitute KPV, GHK-Cu, BPC-157, TB-500 (KLOW).

Materials Needed

Step-by-Step Klow Blend Reconstitution Guide

Why Is KLOW Peptide Blue, and Why Does It Sometimes Sting?

KLOW is blue because of GHK-Cu. The copper(II) ion bound to the GHK tripeptide gives copper-peptide solutions their characteristic blue-to-teal color, and because GHK-Cu is the largest fraction of the blend (50 of 80 mg), reconstituted KLOW takes on that blue tint. A blue color is therefore expected for a correctly made KLOW solution and is not a sign of contamination on its own.

Reports that reconstituted KLOW can sting on contact are usually attributed to two factors: the relatively high total peptide concentration of the blend, and the acidity that some peptide solutions carry after reconstitution. These are general observations from research handling and do not change the fact that KLOW is not intended for human use.

KLOW Peptide Side Effects and Safety Considerations

As a research-use-only material, KLOW has no established human safety profile, and there are no controlled human trials defining its side-effect rate. The most relevant safety information comes from the individual components and from general handling practice:

Anyone evaluating peptide research materials should treat purity and third-party testing as the primary safety factors, since unverified or contaminated material is a larger practical risk than the peptides themselves.

KLOW Peptide FAQ

What is KLOW peptide?

KLOW peptide is a research-use-only blend of four peptides: GHK-Cu, BPC-157, TB-500, and KPV. The common KLOW 80 vial contains 50 mg GHK-Cu and 10 mg each of the other three. It is an extension of the three-peptide GLOW blend, with KPV added.

What does KLOW peptide do?

In preclinical research, each component is studied for a different mechanism: GHK-Cu for collagen and matrix-gene signaling, BPC-157 and TB-500 for cell migration and angiogenesis, and KPV for NF-κB and cytokine modulation. These are model-system findings, not confirmed human effects of the blend.

What is in KLOW peptide?

Four peptides: GHK-Cu (a copper tripeptide), BPC-157 (a pentadecapeptide), TB-500 (a thymosin beta-4 fragment), and KPV (a tripeptide from alpha-MSH). The standard ratio is 50/10/10/10 mg for a total of 80 mg.

What is the difference between KLOW and GLOW?

GLOW contains three peptides (GHK-Cu, BPC-157, TB-500). KLOW contains those same three plus KPV, an anti-inflammatory tripeptide. KLOW is essentially GLOW with one additional component.

Why is KLOW peptide blue?

The blue color comes from the copper in GHK-Cu. Copper-peptide solutions are naturally blue, and since GHK-Cu makes up the largest share of the blend, reconstituted KLOW appears blue.

How is KLOW peptide reconstituted?

In a research setting, bacteriostatic or sterile water is added to the freeze-dried powder. For example, 3 mL of water in an 80 mg vial yields a 26.67 mg/mL solution, where 0.1 mL contains 2.67 mg of total peptide. The exact concentration depends on the volume of water used. This is reference information for laboratory handling, not human dosing guidance.

Is KLOW peptide approved for human use?

No. KLOW and its components are sold as research-use-only materials and are not approved by the FDA or any equivalent body for human consumption, administration, or clinical use.

References

Research Disclaimer

The information presented in this article is for educational and research purposes only. Peptide Mind provides evidence-based research summaries and does not offer medical advice, diagnosis, or treatment recommendations. All peptides discussed are intended for in vitro and preclinical research use only. Consult a qualified healthcare professional before making any health-related decisions. The research cited may not reflect the full body of available evidence, and findings from preclinical studies may not translate to human outcomes. By accessing this site, you confirm you are over the age of 21, waive any claims or liability arising from the use of the content portrayed, and fully indemnify Peptide Mind against any unauthorized usage, claims, or liability in accordance with our Terms of Service.